Inside Amethyst Healthcare’s PPP Strategy with CEO Stephane Carre
In today’s rapidly evolving healthcare landscape, Public–Private Partnerships (PPPs) represent more than just a financial model—they serve as a cornerstone for innovation, increased access, and long-term sustainability. Amethyst Healthcare Group, under the leadership of CEO Stéphane Carré, is championing this approach. In a recent interview with The CEO Magazine, Carré detailed how Amethyst is strategically leveraging PPPs to deliver cutting-edge cancer care to more patients across Europe.
The Role of PPPs in Modern Healthcare
Healthcare systems across Europe are grappling with a dual pressure: tightening budgets and rising demand for services. PPPs present a viable solution by combining the reach and reliability of public institutions with the agility and technological edge of private enterprise. When executed effectively, these partnerships can enhance service quality, increase efficiency, and broaden patient access.
Amethyst has been a firm advocate of this collaborative model since its inception. Through enduring partnerships with hospitals and public health organizations, the company provides advanced radiotherapy services—relieving pressure on public resources while ensuring high standards of patient care. This alignment results in a dual benefit: enhanced healthcare delivery for patients and sustainable models for providers.
Expanding Access Through Real-World Impact
One notable example of Amethyst’s PPP success is its collaboration with Centre Hospitalier de Troyes in France. By managing the hospital’s radiotherapy unit, Amethyst enables the facility to offer cutting-edge treatments without requiring a substantial capital outlay. This approach removes financial and operational barriers, significantly improving access to lifesaving care—especially in underserved regions.
In the UK, the company’s acquisition of Queen Square Radiosurgery Centre in London brought advanced Gamma Knife technology to both private and NHS patients. Since 2023, patient numbers at the center have doubled, underscoring how PPPs can rapidly enhance treatment capacity and introduce breakthrough technologies into public healthcare frameworks.
Driving Innovation While Sharing Risk
One of the key advantages of PPPs is the ability to introduce innovation without placing the entire financial or operational burden on public systems. Amethyst’s model epitomizes this principle. By investing in and managing radiotherapy centers on behalf of public institutions, the Group delivers excellence in care with a streamlined, patient-focused approach.
This model not only facilitates faster adoption of advanced technology but also enhances overall service quality—reducing waiting times, minimizing inefficiencies, and improving patient outcomes.
Scaling for Sustainable Impact
Since 2020, Amethyst has recorded an 84% increase in the number of patients treated annually, including a 70.1% rise in NHS-referred patients. These figures highlight more than just growth—they reflect the potential of PPPs to sustainably expand healthcare capacity and ease the burden on national systems like the NHS.
Looking ahead, Amethyst plans to scale its operations to 50 clinics and over 100 linear accelerators across Europe. This ambitious expansion is firmly anchored in its PPP-driven strategy, which remains a central pillar of the Group’s vision for the future.
Redefining Collaborative Healthcare
For Amethyst, PPPs are not merely funding mechanisms—they are strategic enablers. By aligning the capabilities of the private sector with the needs of the public, these partnerships create resilient systems that can grow, adapt, and consistently deliver high-quality care.
As Stéphane Carré noted in his interview with The CEO Magazine, the future of healthcare lies in intelligent collaboration. PPPs will continue to play a transformative role—not just in oncology, but across all sectors of healthcare seeking scalable, impactful, and sustainable solutions. Amethyst Healthcare is proud to be leading this transformation.